Streetbeat News

Revenues

OCEA

Ocean Biomedical announced that its joint venture partner, Virion Therapeutics, will present clinical study data at the 2024 APASL Global Liver Meeting. This presentation could highlight significant advancements in liver disease treatment, potentially impacting Ocean Biomedical's reputation and future prospects.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:49 pm

AUUD

Auddia Inc. is expected to see ad revenue growth from its proposed acquisition of Radio FM, leveraging improved ad market rates and optimized programmatic CPMs. The near-term integration of Auddia's AI into the Radio FM app aims to offer a premium ad-free AM/FM listening experience for subscribers and provide Auddia's ad-free podcast partners access to a global user base.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:45 pm

SPY

The PCE Price Index for January showed a year-over-year increase of 2.4%, aligning with the expectations.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:32 pm

BTCY

Biotricity Inc. has received Health Canada clearance for its Biotres device, a significant regulatory approval that allows the company to market this device in Canada. This clearance is a crucial step for Biotricity, expanding its potential market and possibly impacting its revenue positively in the short term.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:26 pm

VRNOF

Verano Holdings Corp. (VRNOF) reported a Q4 revenue of $237 million, a 5% increase year-over-year but a 1% decrease from the previous quarter. The company experienced a higher net loss of $(73) million compared to $(18) million in Q3. For the full year 2023, revenue was $938 million, up from $879 million in 2022, with a net loss of $(113) million, an improvement from $(269) million. CEO George Archos expressed optimism for 2024, citing potential growth opportunities and legislative changes. The company forecasts a 5-7% revenue decline in Q1 2024 due to market normalization in New Jersey. Shares closed 2.21% lower at $5.38.

Portfolio Pulse from Nina Zdinjak

February 29, 2024 | 1:14 pm

ARLO

Arlo Technologies, Inc. has achieved a significant milestone by surpassing 3 million paid subscription accounts, demonstrating the success of its continuous innovation and the robustness of its hardware and software solutions.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:11 pm

CRAI

CRA International projects its FY24 revenue to be in the range of $645M-$675M, surpassing the estimated $630.81M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:10 pm

VCEL

Vericel projects its 2024 revenue to be between $237M and $241M, closely aligning with the consensus estimate of $240.24M. The company also anticipates a gross margin of around 70% and an adjusted EBITDA margin of about 20%.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:08 pm

SLS

SELLAS Life Sciences announced it will present Phase 1 data for SLS009 from Acute Myeloid Leukemia patients at the 2024 ESH Conference. This marks a significant milestone in the development of SLS009 and its potential impact on treating Acute Myeloid Leukemia.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:06 pm

PCRX

Pacira BioSciences projects its 2024 revenue to be between $680M-$705M, which is below the consensus estimate of $716.62M. The company also anticipates an adjusted gross margin of 74%-76%.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:06 pm